{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%2B+PEGinterferon+alfa-2a&page=2", "query": { "intervention": "placebo + PEGinterferon alfa-2a", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 56, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%2B+PEGinterferon+alfa-2a&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%2B+PEGinterferon+alfa-2a&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T18:41:10.463Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01054729", "title": "Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2010-01", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 6, "location_summary": "San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01054729" }, { "nct_id": "NCT00963885", "title": "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO5190591 (Danoprevir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2009-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963885" }, { "nct_id": "NCT00983853", "title": "Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "telaprevir or matching placebo", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin (fixed dose)", "type": "DRUG" }, { "name": "ribavirin (weight-based dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 62, "start_date": "2009-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-10-10", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 11, "location_summary": "Beverly Hills, California • San Diego, California • San Francisco, California + 8 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00983853" }, { "nct_id": "NCT01281839", "title": "An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon alpha-2a (PegIFN alpha-2a)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 394, "start_date": "2011-02", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-04-23", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 11, "location_summary": "Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281839" }, { "nct_id": "NCT01616524", "title": "Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus (HCV)" ], "interventions": [ { "name": "Pegylated interferon lambda (pegIFNλ)", "type": "BIOLOGICAL" }, { "name": "Pegylated interferon alfa-2a (pegIFNα-2a)", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo matching Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2012-07", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 18, "location_summary": "Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01616524" }, { "nct_id": "NCT01485991", "title": "TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "TVR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 771, "start_date": "2012-02", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2016-04-26", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 32, "location_summary": "Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485991" }, { "nct_id": "NCT00516321", "title": "Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "eltrombopag", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2007-10", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2013-11-05", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516321" }, { "nct_id": "NCT01323244", "title": "A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 142, "start_date": "2011-12", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2016-04-04", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 15, "location_summary": "Bakersfield, California • Los Angeles, California • San Diego, California + 12 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323244" }, { "nct_id": "NCT00882908", "title": "A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Ribavirin (R)", "type": "DRUG" }, { "name": "PegIFNα-2a (P)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 386, "start_date": "2009-06", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2014-06-16", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 12, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882908" }, { "nct_id": "NCT01482403", "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "boceprevir", "type": "DRUG" }, { "name": "mericitabine", "type": "DRUG" }, { "name": "mericitabine placebo", "type": "DRUG" }, { "name": "boceprevir placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-10-05T18:41:10.463Z", "location_count": 7, "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482403" } ] }